Insilico Medicine, a Baltimore-based next-generation artificial intelligence company specialized in the application of deep learning for target identification, drug discovery and aging research, completed a strategic round of funding of undisclosed amount.
The round was led by WuXi AppTec’s Corporate Venture Fund with participation from Pavilion Capital, a subsidiary of Temasek Holdings, Bold Capital Partners, the venture capital fund investing in exponential technologies co-founded by Peter Diamandis, and Juvenescence.
WuXi AppTec’s strategic investment was conditional upon the successful experimental validation of Insilico Medicine’s Generative Adversarial Networks (GAN) and Reinforcement Learning (RL)-based drug discovery pipeline and is intended to closely integrate the company’s artificial intelligence technology with WuXi AppTec’s laboratory infrastructure and expertise in drug discovery.
The company will use the funds to enhance its work in the innovative approaches to the generation of novel molecules using a variety of machine learning and deep learning techniques, as well as to expand a variety of the biomarker discovery initiatives.
Led by Dr. Alex Zhavoronkov, Founder and CEO, Insilico Medicine is an artificial intelligence company dedicated to advancing applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging.
The company has R&D and management resources in Belgium, Russia, UK, Taiwan and Korea.